Cobalt Capital Management’s Teva Pharmaceuticals TEVA Stock Holding History

Cobalt Capital Management’s Portfolio TEVA Stock Details TEVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.03M	Buy	60,000 +35,000	+140%	+$1.17M	1.45%	14
2026 Q1	$753K	Sell	25,000 -93,201	-79%	-$3M	0.42%	22
2025 Q4	$3.69M	Buy	+118,201	New	+$2.91M	1.63%	16
2025 Q3	–	Sell	-220,000	Closed	-$3.69M	–	33
2025 Q2	$3.69M	Buy	+220,000	New	+$3.55M	1.73%	15
2025 Q1	–	Sell	-10,000	Closed	-$220K	–	33
2024 Q4	$220K	Buy	+10,000	New	+$182K	0.09%	27
2024 Q2	–	Sell	-50,700	Closed	-$715K	–	31
2024 Q1	$715K	Buy	+50,700	New	+$639K	0.23%	23

Other funds holding TEVA

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

HIIFS

Harel Insurance Investments & Financial Services Ramat Gan, Israel $20.6B AUM 59.59% 1-Year Est. Return

Phoenix Financial Givatayim, Israel $14.6B AUM 57.48% 1-Year Est. Return

WCM Investment Management Laguna Beach, California $55.2B AUM 57.07% 1-Year Est. Return

Clal Insurance Tel-Aviv, Israel $22.3B AUM 79.91% 1-Year Est. Return

MMH

Menora Mivtachim Holdings Ramat Gan, Israel $25.6B AUM 50.04% 1-Year Est. Return

MIFH

Migdal Insurance & Financial Holdings Petach Tikva, Israel $15.6B AUM 71.29% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

LIM

Lingotto Investment Management London, United Kingdom $4.67B AUM 70.24% 1-Year Est. Return

Cobalt Capital Management's TEVA Position: Q2 2026 in Review

Cobalt Capital Management increased its Teva Pharmaceuticals (TEVA) stake by 140% in Q2 2026, buying an estimated $1.17M and bringing the position to 60,000 shares worth $2.03M. The position accounts for 1.45% of the portfolio, ranked #14.

Cobalt Capital Management first reported a position in TEVA in Q1 2024 and has held it in 6 quarters since. The position peaked at $3.69M in Q4 2025. 673 funds tracked by Wall St. Rank hold TEVA as of Q2 2026.

Cobalt Capital Management held 60,000 shares of Teva Pharmaceuticals worth $2.03M as of Q2 2026.
Cobalt Capital Management bought 35,000 Teva Pharmaceuticals shares in Q2 2026, an estimated $1.17M.
Teva Pharmaceuticals made up 1.45% of Cobalt Capital Management's portfolio in Q2 2026, its #14 holding.
Cobalt Capital Management first reported a position in Teva Pharmaceuticals in Q1 2024 and has held it in 6 quarters since.
Cobalt Capital Management's Teva Pharmaceuticals position peaked at $3.69M in Q4 2025.
673 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q2 2026.

Based on Cobalt Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.